Tomas Vrba
Sources and care
Source Notes · Care Conversations · Culture desk
About
Traces a claim back to where it was published, what kind of study produced it, and how far its conclusions can travel before they break. Also drafts the questions worth bringing to a dermatologist or clinician, and says plainly when a general article has reached the edge of what it can responsibly answer.
The habit is checking the source before the summary: study design, sample size, funding, and date, since skin care research ages faster than it gets cited. Reads the original paper or filing before repeating its conclusion, and separates a professional's individualized advice from what a general audience can safely take away. Will not present a single study or a single consult as settled science.
Desks
Contact
Published work 11 articles since 2026
-
FDA's 'first oral drug' claim for dermatomyositis needs a footnote
Lisraya is the first oral therapy approved for dermatomyositis, not the first drug overall, and its pivotal trial only compared the drug to placebo, not to existing options.
-
The Fibroblast "Collapse" Theory of Skin Aging Is Eighteen Years Old. This Paper Adds the Missing In Vivo Evidence.
A new JID paper claims fibroblast collapse drives skin aging "in vivo," but the underlying mechanism was first proposed in 2008 and tested mostly in culture and mice until now.
-
A New Comment Pushes Back on the Reassuring Isotretinoin Height Study
A JAAD comment challenges a Mayo Clinic cohort study that found isotretinoin doesn't shorten teens' final height, pointing instead to the slowed growth velocity the study measured along the way.
-
The Fine Print Behind a 'First' Acne Treatment
Clear Health markets Isoclear as the first prescription topical isotretinoin system available in the United States, but its own product page discloses that the clinical evidence behind it comes from the ingredient generally, including products once sold abroad, not from trials of this specific formulation.
-
UPF Standards Were Written for Textiles, Not Sun Patches
An August review suggests UPF labeling for adhesive sun patches, but current AATCC and ASTM standards address textile fabrics and products. The supporting SPF 100 result came from instrument testing of an experimental material, leaving retail patches without a clean comparison to sunscreen or clothing labels.
-
Isotretinoin's Label Never Demanded Monthly Blood Draws
A new JAMA Dermatology viewpoint argues most isotretinoin patients don't need routine liver and lipid testing, but the drug's FDA-approved label never actually specified the monthly schedule that became dermatology's default. That habit was built by clinical culture over three decades, not by regulation, and it is the fourth step in a ten-year sequence of evidence pulling practice back toward what the label always allowed.
-
The Face-Mask Giant Publishing Its Own Stability Science
A new light-scattering method for catching early emulsion breakdown, built to spot phase separation and freeze damage before they're visible, comes from the quality-control lab of one of the world's largest cosmetics contract manufacturers, whose factories make face masks and skincare sold under hundreds of other companies' names.
-
The Drug a New Skin-Peptide Review Cites Already Changed Its Name
A new review of antimicrobial peptides in skin cancer names LTX-315 as a clinical candidate, but the compound is a synthetic redesign of a cow's-milk peptide, not a skin peptide, and it had already been renamed ruxotemitide and moved through two Phase II melanoma trials by the time the review reached print.
-
The Six-Patient Study Underneath an Interim Readout
A 40-patient Phase 2 trial of the topical gel TolaSure for epidermolysis bullosa simplex is nearing an interim data check, but the predecessor study its confidence rests on enrolled six adults instead of the ten planned and still has no results posted on ClinicalTrials.gov more than three years after it ended.
-
The Gene Signature Is Not Yet an Atopic Dermatitis Test
The paper finds a recurring gene-expression signature across archived atopic dermatitis datasets. It does not establish a clinical diagnostic test: metabolism and immune cells were inferred from transcriptomic data, and no prospective diagnostic cohort or locked assay was evaluated.
-
A Diagnosis That Barely Shows Up in the Record
A search of the public archive of U.S. appellate opinions turns up only two published cases that ever use the clinical term delusional parasitosis, and in neither one is the diagnosis itself what the court had to decide.